Niall Lennon, Ph.D.
Director of the Genomics Platform, Chief Scientific Officer and Chair of the Board of Broad Clinical Laboratories, Institute Scientist
Niall Lennon is the director of the genomics platform at the Broad Institute of MIT and Harvard, where he is also an institute scientist. He is also the chief scientific officer and chair of the board of Broad Clinical Laboratories; an associate director of the Gerstner Center for Cancer Diagnostics; and an adjunct professor of biomedical engineering at Tufts University, where he teaches molecular biotechnology. He oversees the development, implementation, and validation of disruptive technologies to serve basic research, clinical research, and clinical diagnostics.
Lennon has been with the Broad since 2006, and has contributed to the development of applications for every major massively parallel sequencing platform across a range of fields. Lennon also built a CLIA/CAP licensed clinical laboratory at the Broad to facilitate return of results to patients and to support clinical trials. More recently, Lennon has led efforts to achieve FDA approval for both large-scale genomics projects (NIH’s All of Us Research Program) and for Broad’s own clinical diagnostic for COVID-19 testing process that delivered more than 37M diagnostic test results to people in the New England region.
He received a Ph.D. in pharmacology from University College Dublin and completed his postdoctoral studies at Harvard Medical School and Massachusetts General Hospital. He holds an executive certificate in management from the MIT Sloan School of Management.